Forst, Thomas

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 638

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study

Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 565

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 486

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 262

Pilot Study for Assessment of Optimal Frequency for Changing Catheters in Insulin Pump Therapy—Trouble Starts on Day 3

Schmid, V., Hohberg, C., Borchert, M., Forst, T., & Pfützner, A. (2010) · Journal of Diabetes Science and Technology

Diabetes Management and ResearchIntravenous Infusion Technology and Safety

Cited by 97

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

Forst, T., Michelson, G., Ratter, F., Weber, M. M., Anders, S., Mitry, M., Wilhelm, B., & Pfützner, A. (2012) · Diabetic Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 75

Impact of environmental temperature on skin thickness and microvascular blood flow in subjects with and without diabetes

Forst, T., Caduff, A., Talary, M., Weder, M., Brändle, M., Kann, P., Flacke, F., Friedrich, C., & Pfützner, A. (2006) · Diabetes Technology & Therapeutics

Skin Diseases and DiabetesDiabetes Management and Research

Cited by 51

Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control

Forst, T., Weber, M. M., & Pfützner, A. (2012) · Experimental Diabetes Research

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 44

Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills

Pfützner, A., Schipper, C., Niemeyer, M., Qvist, M., Löffler, A., Forst, T., & Musholt, P. B. (2012) · Journal of Diabetes Science and Technology

Diabetes Management and ResearchDiabetes Management and Education

Cited by 37

Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 25